Study Of An Anti-HER3 Antibody, HMBD-001, With Or Without Chemotherapy In Patients With Solid Tumors Harboring An NRG1 Fusion Or HER3 Mutation

Study Overview

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

N/A

Non-Small Cell Lung Cancer
Pancreatic Cancer
Locally Advanced Solid Tumor
Metastatic Solid Tumor

DRUG: HMBD-001
DRUG: Docetaxel
DRUG: Nab-paclitaxel
DRUG: Gemcitabine

HMBD-001-102

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2023-06-01	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-04-17
First Submitted that Met QC Criteria 2023-06-16	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2025-04-18
First Posted (ACTUAL) 2023-06-26	Results First Posted N/A	Last Verified 2025-04

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Arm A Participants with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) harboring NRG1 gene fusions	DRUG: HMBD-001 HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly DRUG: Nab-paclitaxel Nab-paclitaxel 125 mg/m^2 IV on days 1, 8, 15, every 4 weeks DRUG: Gemcitabine Gemcitabine 1000 mg/m^2 IV on days 1, 8, 15, every 4 weeks
EXPERIMENTAL: Arm B Participants with non-small cell lung cancer (NSCLC) harboring NRG1 gene fusions	DRUG: HMBD-001 HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly DRUG: Docetaxel Docetaxel 75 mg/m^2 IV once every 3 weeks
EXPERIMENTAL: Arm C Participants with other solid tumors harboring NRG1 gene fusions	DRUG: HMBD-001 HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
EXPERIMENTAL: Arm D Participants with solid tumors harboring selected HER3 extracellular mutations	DRUG: HMBD-001 HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly

Primary Outcome Measures	Measure Description	Time Frame
Incidence and Nature of Adverse Events (AEs)	An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered to be related to the study treatment.	From the time the ICF is signed until 30 days after last dose of study treatment
Arm A and B only: Incidence and nature of dose-limiting toxicities (DLTs) during the first cycle of treatment	DLTs will be assessed during the safety run-in phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (4 weeks for Arm A, 3 weeks for Arm B) of treatment	Arm A: During the first four weeks of study treatment Arm B: During the first three weeks of study treatment
Objective Response Rate (ORR) by RECIST V1.1	The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1	Up to 24 months

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Ability to understand and be willing to sign an informed consent form

Males and females aged over 18 years
Eastern Cooperative Oncology Group (ECOG) status of 0 to 1
Histologic or cytologic evidence of an advanced malignant solid that is resistant/refractory to standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy in the physician's judgment likely to result in clinical benefit, or the participant has demonstrated to be intolerable to such therapy, or if such therapy has been refused by the participant
Arms A, B and C: Cancer harboring an NRG1 gene fusion with EGF-like domain; Arm A: Participants with locally advanced or metastatic pancreatic adenocarcinoma that have not received prior treatment with gemcitabine or nab-paclitaxel and /or have not received more than 2 lines of systemic therapy for advanced disease; Arm B: Participants with locally advanced or metastatic non-small cell lung cancer that have not received prior treatment with docetaxel and /or have not received more than 2 lines of systemic therapy for advanced disease; Arm C: Participants must not be eligible to participate in Arm A or B
Arm D: Cancer harboring selected HER3 mutations limited to the extracellular domain.
Have an estimated life expectancy of at least 3 months
Have an archival tumour sample available or have a site of disease amenable to biopsy and be willing to undergo a biopsy prior to the receipt of the assigned study treatment
Have adequate organ function
Females must be non-pregnant and non-lactating, willing to use a highly effective method of contraception from screening until study completion or be either surgically sterile or post-menopausal
Males must be surgically sterile, abstinent, or if engaged in sexual relations with a woman of child-bearing potential, the participant and his partner must be surgically sterile or using an acceptable, highly effective contraceptive method from screening until study completion

Prior treatment with HMBD-001, pertuzumab, or an agent that specifically targets HER3, including pan-HER tyrosine kinase inhibitors

Persistent clinically significant toxicities (Grade ≥2) from previous anti-cancer therapy except for Grade >2 toxicities that are considered unlikely to put the participant at an increased risk of treatment-related toxicity and/or impact the study results e.g., alopecia
Most recent anti-cancer therapy including radiotherapy at least 4 weeks, or nitrosourea or mitomycin 3 at least 6 weeks, or 5 half-lives whichever is shorter prior to starting the assigned study treatment
Symptomatic primary Central Nervous System (CNS) cancer or metastases unless the symptoms are stable for at least 28 days prior to the first dose of the study drug and any symptoms have returned to baseline
Evidence of abnormal cardiac function
History of uncontrolled allergic reactions and/or known expected hypersensitivity to the study drugs used in the treatment arm to which the participant is to be enrolled into
Any other known active malignancy except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer
Any uncontrolled illness or significant uncontrolled condition(s) requiring systemic treatment
Known Human Immunodeficiency Virus (HIV) infection
Active hepatitis B or hepatitis C infection
Pregnant or breast feeding
COVID 19 infection within 3 months prior to the first dose of the study drug
COVID 19 vaccination within 14 days prior to the first dose of the study drug

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record